Literature DB >> 12068026

Natural history and treatment of renal involvement in Fabry disease.

Mary Branton1, Raphael Schiffmann, Jeffrey B Kopp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12068026

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  37 in total

1.  High prevalence of subclinical hypothyroidism in patients with Anderson-Fabry disease.

Authors:  A C Hauser; A Gessl; M Lorenz; T Voigtländer; M Födinger; G Sunder-Plassmann
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Fabry disease and nephrogenic diabetes insipidus.

Authors:  Philip Wornell; Sarah Dyack; John Crocker; Weiming Yu; Philip Acott
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

Review 3.  Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.

Authors:  Marianne Rohrbach; Joe T R Clarke
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.

Authors:  A Pisani; L Spinelli; B Visciano; I Capuano; M Sabbatini; E Riccio; G Messalli; M Imbriaco
Journal:  JIMD Rep       Date:  2012-10-21

5.  Foot process effacement with normal urinalysis in classic fabry disease.

Authors:  Takahiro Kanai; Takanori Yamagata; Takane Ito; Jun Odaka; Takashi Saito; Jun Aoyagi; Masahisa Kobayashi; Toya Ohashi; Yoshihiko Ueda; Mariko Y Momoi
Journal:  JIMD Rep       Date:  2011-06-22

6.  The co-existence of Fabry and celiac diseases: a case report.

Authors:  Leyla Tümer; Fatih S Ezgü; Alev Hasanoğlu; Buket Dalgiç; Sevcan A Bakkaloğlu; Leyla Memiş; Ayşe Dursun
Journal:  Pediatr Nephrol       Date:  2004-04-15       Impact factor: 3.714

7.  A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.

Authors:  Atsumi Taguchi; Hiroki Maruyama; Masaaki Nameta; Tadashi Yamamoto; Junichiro Matsuda; Ashok B Kulkarni; Hidekatsu Yoshioka; Satoshi Ishii
Journal:  Biochem J       Date:  2013-12-15       Impact factor: 3.857

Review 8.  Enzyme replacement therapy of Fabry disease.

Authors:  Joe T R Clarke; R Mark Iwanochko
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

9.  Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

Authors:  Raphael Schiffmann; David G Warnock; Maryam Banikazemi; Jan Bultas; Gabor E Linthorst; Seymour Packman; Sven Asger Sorensen; William R Wilcox; Robert J Desnick
Journal:  Nephrol Dial Transplant       Date:  2009-02-13       Impact factor: 5.992

10.  Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.

Authors:  Jin-Ok Choi; Mi Hee Lee; Hae-Young Park; Sung-Chul Jung
Journal:  J Biomed Sci       Date:  2010-04-16       Impact factor: 8.410
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.